Osteoarthritis Market Size and Trend Report including Epidemiology and Pipeline Analysis, Competitor Assessment, Unmet Needs, Clinical Trial Strategies and Forecast, 2021

Osteoarthritis (OA) is the most common joint disease and a major cause of disability and pain among the elderly in the western world. It is a slowly progressive joint disease characterized by degradation of the articular (hyaline) cartilage that coats the bone proximities of synovial joints. The exact cause of OA is not completely understood. Multiple risk factors have been associated with the disease, including age, joint trauma, altered biomechanics, obesity, and excessive load bearing. The sites mainly affected are the weight-bearing bones such as knees, hips, spine, and feet, as well as the hands.

The Osteoarthritis (OA) market is currently at an important commercial juncture. The OA market has been largely a pain market, and as such, is highly genericized. However, the market is expected to evolve significantly over the next 10 years as drug manufacturers improve on current pain medication through novel mechanisms of action and move towards developing disease modifying osteoarthritis drugs (DMOAD).

Key Highlights

The greatest drivers of growth in the global OA market include the launch of eight new pipeline therapies during the forecast period and a steadily climbing diagnosed prevalence in many 7MM countries
The main barriers to growth in the OA market include overcrowding of the well-established and highly genericized pain market, limited locations of launch for new pipeline products and the slowed growth of the opioid market
Among the late-stage innovator pipeline products, three are disease modifying osteoarthritis drugs and five are novel analgesics, two of which use novel mechanisms of action
The most important unmet needs in the OA market are the need for disease modifying OA drugs and novel analgesics with improved efficacy and safety

KEY QUESTIONS ANSWERED

Which unmet needs are limiting the treatment of OA in the 7MM?
What strategies can the pharmaceutical industry employ to increase treatment rates for OA? How should these strategies differ across different geographical markets?
What effect will the launch of novel DMOADs have on the OA market?
What are the main R&D trends in the OA market and which companies are leading the way? Are there major differences in the mechanisms of action used by current versus late-stage clinical development?

Scope

Overview of OA including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and treatment guidelines
Topline OA market revenue, annual cost of therapy, and major pipeline product sales in the forecast period
Key topics covered include current treatment and pipeline therapies, unmet needs and opportunities, and the drivers and barriers affecting OA therapeutics sales in the 7MM
Pipeline analysis: Comprehensive data split across different phases, emerging novel trends under development and detailed analysis of late-stage pipeline drugs
Analysis of the current and future market competition in the OA therapeutics market across the 7MM. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications

Reasons to Buy

The report will enable you to -

Develop and design your in-licensing and out-licensing strategies, using a detailed overview of current pipeline products and technologies to identify companies with the most robust pipelines
Develop business strategies by understanding the trends shaping and driving the global OA therapeutics market
Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global OA market in the future
Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors
Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage
Track drug sales in the global OA therapeutics market from 2021-2031
Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships

1 Osteoarthritis: Executive Summary

1.1 OA market expected to experience conservative growth from 2021-31
1.2 New players to enter a saturated field
1.3 Clinical unmet needs and opportunities
1.4 DMOADs to expand OA treatment options
1.5 What do physicians think?

2 Introduction

2.1 Catalyst
2.2 Related reports
2.3 Upcoming reports

3 Disease Overview

3.1 Etiology and pathophysiology
3.1.1 Etiology
3.1.2 Pathophysiology
3.1.3 Symptoms
3.2 Classification or staging systems

4 Epidemiology

4.1 Disease background
4.2 Risk factors and comorbidities
4.3 Global and historical trends
4.4 Forecast methodology
4.4.1 Sources used
4.4.2 Forecast assumptions and methods
4.4.3 Forecast assumptions and methods: total prevalent cases (radiographic)
4.4.4 Forecast assumptions and methods: total prevalent cases (symptomatic)
4.4.5 Forecast assumptions and methods: diagnosed prevalent cases (symptomatic)
4.4.6 Forecast assumptions and methods: diagnosed prevalent cases (symptomatic) by severity
4.5 Epidemiological forecast for OA (2021-31)
4.5.1 Total prevalent cases (radiographic) of hand OA
4.5.2 Total prevalent cases (symptomatic) of hand OA
4.5.3 Diagnosed prevalent cases (symptomatic) of hand OA
4.5.4 Age-specific diagnosed prevalent cases (symptomatic) of hand OA
4.5.5 Sex-specific diagnosed prevalent cases (symptomatic) of hand OA
4.5.6 Diagnosed prevalent cases (symptomatic) of hand OA by severity
4.5.7 Total prevalent cases (radiographic) of knee OA
4.5.8 Total prevalent cases (symptomatic) of knee OA
4.5.9 Diagnosed prevalent cases (symptomatic) of knee OA
4.5.10 Age-specific diagnosed prevalent cases (symptomatic) of knee OA
4.5.11 Sex-specific diagnosed prevalent cases (symptomatic) of knee OA
4.5.12 Diagnosed prevalent cases (symptomatic) of knee OA by severity
4.5.13 Total prevalent cases (radiographic) of hip OA
4.5.14 Total prevalent cases (symptomatic) of hip OA
4.5.15 Diagnosed prevalent cases (symptomatic) of hip OA
4.5.16 Age-specific diagnosed prevalent cases (symptomatic) of hip OA
4.5.17 Sex-specific diagnosed prevalent cases (symptomatic) of hip OA
4.5.18 Diagnosed prevalent cases (symptomatic) of hip OA by severity
4.6 Discussion
4.6.1 Epidemiological forecast insight
4.6.2 COVID-19 impact
4.6.3 Limitations of analysis
4.6.4 Strengths of analysis

5 Disease Management

5.1 Diagnosis and treatment overview
5.1.1 Diagnosis
5.1.2 Treatment paradigm
5.2 Insights on disease management by location

6 Competitive Assessment

6.1 Overview

7 Unmet Needs and Opportunity Assessment

7.1 Overview
7.2 Disease-modifying OA drugs to halt the progression of OA
7.3 Analgesics with improved efficacy and safety profiles
7.4 Therapies to treat OA in patients with comorbid conditions
7.5 Improved patient adherence to non-pharmacological treatments

8 R&D Strategies

8.1 Overview
8.1.1 Development of analgesics with novel MOA to improve tolerability and efficacy
8.1.2 Development of a DMOAD
8.1.3 Development of combination therapy
8.1.4 Strategic partnerships
8.2 Clinical trials design
8.2.1 Limitations of pain and patient-reported outcomes as primary outcomes
8.2.2 Lack of consensus on imaging as a primary endpoint in DMOAD trial design
8.2.3 Improved assessment of joint tissue biology

9 Pipeline Assessment

9.1 Overview
9.2 Promising drugs in clinical development

10 Pipeline Valuation Analysis

10.1 Overview
10.2 Competitive Assessment
10.2.1 Analgesic drugs
10.2.2 DMOAD pipeline therapies

11 Current and Future Players

11.1 Overview
11.2 Deal-making trends

12 Market Outlook

13 Appendix

Contact the Publisher

List of Tables

Table 1: Osteoarthritis: key metrics in the 7MM
Table 2: Etiology of OA
Table 3: Kellgren Lawrence Grading System
Table 4: Risk factors and comorbid conditions associated with OA
Table 5: Severity scoring system for classifying the hand, knee, and hip OA using the KL grading scale
Table 6: Current treatment recommendations for hand, knee, and hip osteoarthritis
Table 7: Current treatment options for osteoarthritis
Table 8: Clinical trial design of key pipeline drugs for osteoarthritis, 2022
Table 9: Top completed deals in OA market by value, 2015-22
Table 10: OA market - global (7MM) drivers and barriers, 2021-31
Table 11: Key events impacting sales for OA in the US, 2021-31
Table 12: OA market - drivers and barriers in the US, 2021-31
Table 13: Key events impacting sales for OA in the 5EU, 2021-31
Table 14: OA market - drivers and barriers in the 5EU, 2021-31
Table 15: Key events impacting sales for OA in Japan, 2021-31
Table 16: OA market - drivers and barriers in Japan, 2021-31
Table 17: High-prescribing physicians (non-KOLs) surveyed, by country

List of Figures

Figure 1: Global (7MM) sales forecast by country for osteoarthritis in 2021 and 2031
Figure 2: Analysis of the company portfolio gap in osteoarthritis during the forecast period
Figure 3: Competitive assessment of the late-stage analgesic pipeline agents that the publisher expects to be licensed for the treatment of osteoarthritis during the forecast period
Figure 4: Competitive assessment of the late-stage DMOAD pipeline agents that the publisher expects to be licensed for the treatment of osteoarthritis during the forecast period
Figure 5: Main structures of a healthy joint and a joint affected by OA
Figure 6: 7MM, diagnosed prevalence (symptomatic) (%), hand OA, both sexes, ages =18 years, 2021
Figure 7: 7MM, diagnosed prevalence (symptomatic) (%), knee OA, both sexes, ages =18 years, 2021
Figure 8: 7MM, diagnosed prevalence (symptomatic) (%), hip OA, both sexes, ages =18 years, 2021
Figure 9: 7MM, sources used to forecast the total prevalent cases (radiographic), hand OA
Figure 10: 7MM, sources used to forecast the total prevalent cases (radiographic), knee OA
Figure 11: 7MM, sources used to forecast the total prevalent cases (radiographic), hip OA
Figure 12: 7MM, sources used to forecast the total prevalent cases (symptomatic), hand OA
Figure 13: 7MM, sources used and not used to forecast the total prevalent cases (symptomatic), knee OA
Figure 14: 7MM, sources used and not used to forecast the total prevalent cases (symptomatic), hip OA
Figure 15: 7MM, total prevalent cases (radiographic) of hand OA, both sexes, ages =18 years, N, 2021
Figure 16: 7MM, total prevalent cases (symptomatic) of hand OA, both sexes, ages =18 years, N, 2021
Figure 17: 7MM, diagnosed prevalent cases (symptomatic) of hand OA, both sexes, ages =18 years, N, 2021
Figure 18: 7MM, age-specific diagnosed prevalent cases (symptomatic) of hand OA, both sexes, ages =18 years, N, 2021
Figure 19: 7MM, sex-specific diagnosed prevalent cases (symptomatic) of hand OA, both sexes, ages =18 years, N, 2021
Figure 20: 7MM, diagnosed prevalent cases (symptomatic) of hand OA by severity, both sexes, ages =18 years, N, 2021
Figure 21: 7MM, total prevalent cases (radiographic) of knee OA, both sexes, ages =18 years, N, 2021
Figure 22: 7MM, total prevalent cases (symptomatic) of knee OA, both sexes, ages =18 years, N, 2021
Figure 23: 7MM, diagnosed prevalent cases (symptomatic) of knee OA, both sexes, ages =18 years, N, 2021
Figure 24: 7MM, age-specific diagnosed prevalent cases (symptomatic) of knee OA, both sexes, ages =18 years, N, 2021
Figure 25: 7MM, sex-specific diagnosed prevalent cases (symptomatic) of knee OA, both sexes, ages =18 years, N, 2021
Figure 26: 7MM, diagnosed prevalent cases (symptomatic) of knee OA by severity, both sexes, ages =18 years, N, 2021
Figure 27: 7MM, total prevalent cases (radiographic) of hip OA, both sexes, ages =18 years, N, 2021
Figure 28: 7MM, total prevalent cases (symptomatic) of hip OA, both sexes, ages =18 years, N, 2021
Figure 29: 7MM, diagnosed prevalent cases (symptomatic) of hip OA, both sexes, ages =18 years, N, 2021
Figure 30: 7MM, age-specific diagnosed prevalent cases (symptomatic) of hip OA, both sexes, ages =18 years, N, 2021
Figure 31: 7MM, sex-specific diagnosed prevalent cases (symptomatic) of hip OA, both sexes, ages =18 years, N, 2021
Figure 32: 7MM, diagnosed prevalent cases (symptomatic) of hip OA by severity, both sexes, ages =18 years, N, 2021
Figure 33: Stepped-care approach for the treatment of OA
Figure 34: Unmet needs and opportunities in osteoarthritis
Figure 35: Overview of the development pipeline in osteoarthritis
Figure 36: Key late-stage trials for the promising pipeline agents that the publisher expects to be licensed for osteoarthritis in the 7MM during 2021-31
Figure 37: Competitive assessment of the analgesic pipeline drugs benchmarked against the standards of care, NSAIDs and corticosteroids
Figure 38: Competitive assessment of the DMOAD pipeline drugs benchmarked against the standards of care, NSAIDs and corticosteroids
Figure 39: Analysis of the company portfolio gap in OA during the forecast period
Figure 40: Global (7MM) sales forecast by country for OA in 2021 and 2031
Figure 41: Sales forecast by class for OA in the US in 2021 and 2031
Figure 42: Sales forecast by class for OA in the 5EU in 2021 and 2031
Figure 43: Sales forecast by class for OA in Japan in 2021 and 2031

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

Pfizer
Janssen
GlaxoSmithKline
Bayer
Novartis
Eli Lilly
Merck
Pacira BioSciences
Kolon TissueGene
Biosplice Therapeutics
Organogenesis Holdings
Techfields Pharma
Centrexion Therapeutics
Regeneron
Xalud Therapeutics
Bone Therapeutics

License	Format	Properties	Price
SINGLE USER LICENSE PDF	The product is a PDF.	This is a single user license, allowing one user access to the product.	€9795EUR$10,995USD£8,523GBP
SITE LICENSE PDF	The product is a PDF.	This is a site license, allowing all users within a given geographical location of your organization access to the product.	€19589EUR$21,990USD£17,045GBP
ENTERPRISE LICENSE PDF	The product is a PDF.	This is an enterprise license, allowing all employees within your organization access to the product.	€29384EUR$32,985USD£25,568GBP

Osteoarthritis Market Size and Trend Report including Epidemiology and Pipeline Analysis, Competitor Assessment, Unmet Needs, Clinical Trial Strategies and Forecast, 2021 - 2031

Key Highlights

Scope

Reasons to Buy

Table of Contents

Companies Mentioned (Partial List)

Key Highlights

Scope

Reasons to Buy

Table of Contents

Companies Mentioned (Partial List)

Related Topics

Related Products

Companion Animal Osteoarthritis Market Size, Share & Trends Analysis Report By Product (Biologics, Viscosupplements, Pharmaceuticals), By Animal (Canine, Feline, Equine), By Route Of Administration, By End Use, By Region, And Segment Forecasts, 2025 - 2033

Osteoarthritis Market Report 2025

Osteoarthritis Therapeutics - Global Strategic Business Report

Knee Osteoarthritis - Pipeline Insight, 2025

Osteoarthritis - Pipeline Insight, 2025